Minimum 20 minute delay
9/15/2014 7:00:54 AMDUBLIN, Ireland--(BUSINESS WIRE)--Sep. 15, 2014-- Covidien plc announced today the start of enrollment in two clinical trials designed to further underscore the safety and effectiveness of the company’s advanced neurovascular solutions. …
8/28/2014 7:00:41 AMTransaction expands Covidien’s market leading portfolio with next generation technology for treatment of varicose veins DUBLIN, Ireland--(BUSINESS WIRE)--Aug. 28, 2014-- Covidien plc (NYSE: COV) today announced that it has acquired …
8/26/2014 8:02:48 AMDUBLIN, Ireland--(BUSINESS WIRE)--Aug. 26, 2014-- In accordance with Rule 2.10 of the Irish Takeover Rules, Covidien plc (NYSE: COV) (the “Company”) confirms that, as of the close of business on August 25, 2014, the Company’s issued share capital, excluding treasury shares, consisted of 451,825,023 ordinary shares, par value …
A Partner in Health
Collaborating with physicians and other healthcare professionals, focusing on research and development and maintaining clinical leadership add up to innovative medical solutions that make a difference.
Ensuring ethical interactions with healthcare professionals is vital to the global healthcare environment. Covidien’s Conscientious Collaboration platform is our commitment to open communications about the need to ensure compliant interactions with our customers and partners.
One look. One Covidien. Experience the new unified look of Covidien. Easy-to-use labeling. New outside packaging with the same quality products inside. First-class service and support.